NEW YORK, June 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Antibacterial Drugs industry
http://www.reportlinker.com/p0197174/Global-Antibacterial-Drugs-industry.html
This report analyzes the worldwide markets for Antibacterial Drugs in US$ Million by the following drug classes: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Other Antibacterial Drugs. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 124 companies including many key and niche players such as Abbott Laboratories, AstraZeneca PLC, Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Pfizer, Inc., and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
ANTIBACTERIAL DRUGS MCP-6168
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Cephalosporins I-3
Penicillins I-3
Fluoroquinolones I-4
Macrolides I-4
Other Antibacterial Drugs I-4
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Global Market Outlook II-1
Antibacterial Resistance - A Key Growth Dampener II-1
Antibacterial Resistance Costs High II-1
Patent Expiries Commoditize Antibacterials Market II-1
Patent Expiries of Major Anti-Bacterial Drugs II-2
Generic Competition Intensifies II-2
Cephalosporins Dominate the Anti-bacterials Market II-2
Table 1: Worldwide Market for Anti-Bacterials by Major Drug
Class (2010): Percentage Share Breakdown for Cephalosporins,
Penicillins, Fluoroquinolones ,Macrolides, and Others
(includes corresponding Graph/Chart) II-3
Macrolides and Fluoroquinolones to Grow At a Faster Rate II-3
Major Players and Key Brands II-3
Table 2: Select Major Anti-Bacterial Drugs Worldwide (2008 &
2007): Value Sales in US$ Million for Levaquin/ Floxin,
Zosyn/Tazocin, Zyvox, Augmentin, Merrem, Primaxin,
Avelox/Avalox, Cravit, Zithromax/Zmax, Cipro/ Ciprobay,
Rocephin (includes corresponding Graph/Chart) II-4
United States Leads the Global Market, Other Regions to
Exhibit Faster Growth II-4
Injectables Gain Traction II-5
2. ANTI-BACTERIAL DRUG CLASSES - A REVIEW II-6
Cephalosporins II-6
Select Major Cephalosporins Worldwide II-6
List of Select Cephalosporin Drugs by Generation II-6
Drug Details of Select Cephalosporins II-7
Omnicef (Abbott Laboratories) II-7
Rocephin (Roche) II-7
Maxipime (Bristol Myers Squibb/Elan) II-7
Zinnat (GlaxoSmithKline) II-7
Spectracef (Cornerstone BioPharma) II-8
Fluoroquinolones II-8
Select Major Fluoroquinolones Worldwide II-9
Drug Details of Select Fluoroquinolones II-9
Levaquin/Floxin/Cravit (Ortho-McNeil-Janssen/ Daiichi Sankyo) II-9
Brand Names of Levofloxacin in Different Regions II-9
Avelox (Bayer) II-10
Ciprofloxacin (Various) II-10
Macrolides II-11
Drug Details of Select Macrolides II-11
Biaxin (Abbott) II-11
Zmax (Pfizer Inc.) II-12
Penicillins II-12
Select Penicillins Worldwide II-13
Table 3: Sales of Leading Penicillin Drugs in US$ Million
(2006-2008) (includes corresponding Graph/Chart) II-13
Drug Details of Select Penicillins II-13
Augmentin (GlaxoSmithKline) II-13
Zosyn (Wyeth) II-14
Other Anti-bacterial Drugs II-14
Other Select Anti-bacterials Worldwide II-14
Details of Other Select Anti-bacterial Drugs Worldwide II-15
Zyvox (Pfizer) II-15
Cubicin (Cubist Pharmaceuticals) II-15
Targocid (Sanofi-Aventis/Astellas) II-16
Vancomycin (Eli Lilly) II-16
Carbapenems II-16
Faropenem (Replidyne) II-16
Primaxin (Merck & Co.) II-16
Merrem/Meronem (AstraZeneca) II-17
3. AN OVERVIEW OF BACTERIAL INFECTIONS AND TREATMENT II-18
Bacterial Infections II-18
Types of Bacteria and Bacterial Infections II-18
Overview of Select Bacterial Infections II-19
Pneumonia II-19
Intra-Abdominal Infections II-19
Central Nervous System Infections II-20
Bloodstream Infections II-21
Bone Infections II-21
Surgical Site Infections II-21
Urinary Tract Infections II-21
Urethritis II-22
Hemorrhagic Cystitis II-22
Acute Pyelonephritis II-22
Anti-bacterial Drugs to Combat Against Bacteria II-22
Launch Year of Different Anti-Bacterial Drug Classes II-23
Anti-bacterial Categorization II-23
Classification Based on Action Mechanism II-23
Classification Based on Method of Suppressing Bacterial Growth II-24
Bactericidal Drugs II-24
Bacteriostatic Drugs II-24
Classification Based on Spectra of Activity II-24
Anti-Bacterial Drug Classes and their Uses II-24
Cephalosporins II-25
Treatment II-25
Side Effects II-25
Penicillins II-25
History II-25
Types of Penicillins II-26
Side Effects II-26
Fluoroquinolones II-26
Treatment II-27
Major Fluoroquinolones Worldwide, Along with Indications II-27
Side Effects II-27
Macrolides II-28
Select Macrolides and its Derivatives by Development Stage
(As of 2008) II-28
Treatment II-28
Side Effects II-29
Other Antibacterials II-29
Aminoglycosides II-29
Treatment II-29
Aminoglycosides and Indications II-30
Side Effects II-30
Tetracyclines II-30
Treatment II-30
Side Effects II-30
Sulfonamides II-30
Treatment II-31
Effects of the Drug II-31
Mupirocin II-31
Carbepenems II-32
Aztreonam II-32
Glycopeptides II-32
Vancomycin II-32
Teicoplanin II-32
Bacitracin II-33
Lincosamines II-33
Polymyxins II-33
Chloramphenicol II-33
Limitations of Antibacterial Therapy II-33
Bacterial Resistance II-33
Antibacterial-Resistant Bacteria by Type II-34
Cross-resistance II-34
Phage Therapy, a Promising Approach for Bacterial Infections II-34
Treatment and Application of Phase Therapy II-35
Phages for Antibiotic-Resistant Bacteria II-35
Companies Involved in Phage Therapy Research II-35
4. PRODUCTS INTRODUCTIONS/APPROVALS/ CLINICAL TRIALS II-36
Johnson & Johnson Receives Complete Response Letter for
Ceftobiprole from US FDA II-36
Negative Opinion on Ceftobiprole by European CHMP II-36
Theravance and Astellas Obtains FDA Approval for VIBATIV™ for
Treating Complicated Skin and Skin Structure Infections
(cSSSI) II-37
Daiichi Sankyo Company Introduces Cravit® Formulations II-37
Forest Labs Announces Encouraging Phase III Results of
Ceftaroline II-37
Cubist Pharma Initiates First-In-Human Clinical Trial with CB-
183,315 II-38
Basilea Pharmaceutica Announces New Research Results for
BAL30072 in Multi- Resistant Gram- Negative Bacteria II-38
Galderma Laboratories Launches Epiduo™ Gel for Acne Treatment II-38
Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug II-38
US FDA Asks Arpida to Secure Additional Data for Iclaprim II-39
MiddleBrook Obtains FDA Approval for MOXATAG™ II-39
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin II-39
Watson Pharma Introduces Biaxin XL's Generic Version II-40
Taisho Toyama Pharmaceutical Rolls Out Zosyn® to Treat Severe
Bacterial Infections II-40
GSK Launches ALTARGO® in the UK II-40
Daiichi Obtains Approval for Gracevit® II-40
New Research Backs LEVAQUIN Use in CAP Treatment in
Concordance with Guidelines II-40
FDA Instructs Targanta to Conduct Additional Oritavancin Trials II-41
J&J's Doribax Obtains FDA Approval for Urinary Tract and
Intra-abdominal Infections II-41
APL Receives FDA Approval for Cefpodoxime Proxetil II-41
Toyama Launches New Garenoxacin Quinolone Antibiotic II-41
Wockhardt to Introduce Cefprozil Tablets in the US II-42
MSD India Launches Invanza in India II-42
Macrolide Antibiotic Developed in the US II-42
GSK Obtains EC Approval for Altargo® in Treating Skin Infections II-42
5. RECENT INDUSTRY ACTIVITY II-43
Pfizer Indicts Teva for Zyvox Patent Infringement II-43
Beactica and Cubist Sign Agreement to Develop Advanced Anti-
Bacterials II-43
Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan
Mingxin II-43
Forest Laboratories Collaborates with AstraZeneca to Co-
Develop Ceftaroline II-44
TB Alliance Enters into Multiple Deals for TB Drug Discovery II-44
Kemin Industries Acquires Amalyte Pharmaceuticals II-44
Forma Therapeutics Sign Deal with Cubist to Make Antibacterial
Drugs II-44
Lee's Pharmaceutical Holdings Acquires Rights to Oral
Antibacterial Drug II-45
Anacor Pharmaceuticals Collaborates with TB Alliance II-45
Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan
Mingxin II-45
Evotec and Cubist Ink Research Pact for Fragment-Based Drug
Discovery II-45
Abbott Acquires Ibis Biosciences II-46
Elder and Strides on Expansion Mode II-46
Pfizer Inks Agreements with Claris Lifesciences and Aurobindo
Pharma II-46
Akorn Signs Agreement with Eli Lilly and Company II-47
NovaBay Inks Agreement with Medical University of Innsbruck II-47
Tibotec Collaborates with Global Alliance for TB Drug Development II-47
Sandoz Introduces Generic Maxipime® II-48
Merck and Ranbaxy to Launch Anti-Bacterial and Anti-Fungal Drugs II-48
Wyeth Receives an Approvable Letter from US FDA for TYGACIL® II-48
Mylan Receives FDA Approval for Linezolid 600 mg Tablets II-49
Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in
Sweden II-49
MiddleBrook Obtains NDA Approval for MOXATAG™ II-49
ULL Establishes New Antibiotics Unit in Himachal Pradesh II-49
Biocat to Expand Presence in the Indian Market II-49
Novartis to Acquire Protez II-49
Orchid Signs Licensing Agreement with Merck II-50
Forest and Novexel Sign Licensing Agreement II-50
Sanofi-aventis Collaborates with Novozymes II-51
AstraZeneca Acquires Arrow Therapeutics II-51
Cubist Submits INDs for CB-182,804 and CB-183,315 II-51
GlaxoSmithKline Enters into Strategic Alliance with Mpex
Pharmaceuticals to Develop Novel Drugs to treat Bacterial
Diseases II-52
Advanced Life Sciences and Wyeth Pharmaceuticals Sign
Marketing Deal for Commercialization of Cethromycin in Asia
Pacific II-52
GlaxoSmithKline Receives FDA Approval for Altabax II-52
GSK and Anacor Team Up for Boron Chemistry-Based Antibiotics
and Antivirals II-52
Cubist Pharmaceuticals Receives Health Canada Approval for
CUBICIN® II-53
Cubist Obtains Approval to Market CUBICIN for Added
Indications in EU II-53
Cubist Gains Approval for CUBICIN in Taiwan and South Korea II-53
Cethromycin Achieves FDA's Orphan Drug Designation II-53
GSK Receives Approval for ALTARGO® in Europe II-54
sanofi-aventis Updates Prescription Information for Ketek in
the US II-54
6. FOCUS ON SELECT GLOBAL PLAYERS II-55
Abbott Laboratories (USA) II-55
AstraZeneca PLC (UK) II-55
Bayer HealthCare AG (Germany) II-55
Bristol-Myers Squibb Co. (USA) II-56
Cubist Pharmaceuticals, Inc. (USA) II-56
Daiichi Sankyo Company, Ltd. (Japan) II-57
GlaxoSmithKline Plc. (UK) II-57
Johnson & Johnson (USA) II-58
Pfizer, Inc. (US) II-58
Wyeth Pharmaceuticals, Inc. (US) II-59
7. GLOBAL MARKET PERSPECTIVE II-60
Table 4: World Recent Past, Current & Future Analysis for
Antibacterial Drugs by Geographic Region - US, Europe,
Asia-Pacific, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart) II-60
Table 5: World 10-Year Perspective for Antibacterial Drugs by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Europe, Asia-Pacific, and Rest of World Markets for Years
2006, 2009, and 2015 (includes corresponding Graph/Chart) II-61
Table 6: World Recent Past, Current & Future Analysis for
Cephalosporins by Geographic Region - US, Europe,
Asia-Pacific, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart) II-62
Table 7: World 10-Year Perspective for Cephalosporins by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Europe, Asia-Pacific, and Rest of World Markets for Years
2006, 2009, and 2015 (includes corresponding Graph/Chart) II-63
Table 8: World Recent Past, Current & Future Analysis for
Penicillins by Geographic Region - US, Europe, Asia-Pacific,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) II-64
Table 9: World 10-Year Perspective for Penicillins by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Europe, Asia-Pacific, and Rest of World Markets for Years
2006, 2009, and 2015 (includes corresponding Graph/Chart) II-65
Table 10: World Recent Past, Current & Future Analysis for
Fluoroquinolones by Geographic Region - US, Europe,
Asia-Pacific, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart) II-66
Table 11: World 10-Year Perspective for Fluoroquinolones by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Europe, Asia-Pacific, and Rest of World Markets for Years
2006, 2009, and 2015 (includes corresponding Graph/Chart) II-67
Table 12: World Recent Past, Current & Future Analysis for
Macrolides by Geographic Region - US, Europe, Asia-Pacific,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) II-68
Table 13: World 10-Year Perspective for Macrolides by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Europe, Asia-Pacific, and Rest of World Markets for Years
2006, 2009, and 2015 (includes corresponding Graph/Chart) II-69
Table 14: World Recent Past, Current & Future Analysis for
Other Anti-bacterial Drugs by Geographic Region - US, Europe,
Asia-Pacific, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart) II-70
Table 15: World 10-Year Perspective for Other Anti-bacterial
Drugs by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Europe, Asia-Pacific, and Rest of World Markets
for Years 2006, 2009, and 2015 (includes corresponding
Graph/Chart) II-71
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Current & Future Analysis III-1
Products Approvals/Launches/Clinical Trials III-1
Strategic Corporate Developments III-5
Key Players III-10
B.Market Analytics III-14
Table 16: US Recent Past, Current & Future Analysis for
Antibacterial Drugs by Drug Class - Cephalosporins,
Penicillins, Fluoroquinolones, Macrolides, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-14
Table 17: US 10-Year Perspective for Antibacterial Drugs by
Drug Class - Percentage Breakdown of Dollar Sales for
Cephalosporins, Penicillins, Fluoroquinolones, Macrolides,
and Others Markets for Years 2006, 2009 & 2015 (includes
corresponding Graph/Chart) III-14
2. EUROPE III-15
A.Market Analysis III-15
Current and Future Analysis III-15
Strategic Corporate Developments III-15
B.Market Analytics III-18
Table 18: European Recent Past, Current & Future Analysis
for Antibacterial Drugs by Region - France, Germany, Italy,
UK, Spain, and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart) III-18
Table 19: European 10-Year Perspective for Antibacterial
Drugs by Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK, Spain, and Rest of Europe
Markets for 2006, 2009 & 2015 (includes corresponding
Graph/Chart) III-19
Table 20: European Recent Past, Current & Future Analysis
for Antibacterial Drugs by Drug Class- Cephalosporins,
Penicillins, Fluoroquinolones, Macrolides, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-20
Table 21: European 10-Year Perspective for Antibacterial
Drugs by Drug Class - Percentage Breakdown of Dollar Sales
for Cephalosporins, Penicillins, Fluoroquinolones,
Macrolides, and Others Markets for Years 2006, 2009 & 2015
(includes corresponding Graph/Chart) III-20
2a. FRANCE III-21
A.Market Analysis III-21
Antibiotics Use Takes A Dip, As Regulatory Authorities'
Efforts Pays Off III-21
B.Market Analytics III-21
Table 22: French Recent Past, Current & Future Analysis for
Antibacterial Drugs- Annual Sales Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-21
2b. GERMANY III-22
A.Market Analysis III-22
Key Player III-22
Bayer HealthCare AG III-22
B.Market Analytics III-23
Table 23: German Recent Past, Current & Future Analysis for
Antibacterial Drugs - Annual Sales Figures in US$ Million
for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-23
2c. ITALY III-24
Market Analysis III-24
Table 24: Italian Recent Past, Current & Future Analysis for
Antibacterial Drugs - Annual Sales Figures in US$ Million
for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-24
2d. THE UNITED KINGDOM III-25
A.Market Analysis III-25
Infectious Diseases - A Quick Primer III-25
Research and Development of New Anti-Infectives III-25
Products Introduction III-26
Strategic Corporate Developments III-26
Key Players III-26
B.Market Analytics III-28
Table 25: UK Recent Past, Current & Future Analysis for
Antibacterial Drugs - Annual Sales Figures in US$ Million
for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-28
2e. SPAIN III-29
Market Analysis III-29
Table 26: Spanish Recent Past, Current & Future Analysis for
Antibacterial Drugs-Annual Sales Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-29
2f. REST OF EUROPE III-30
A.Market Analysis III-30
Strategic Corporate Development III-30
Key Player III-30
F. Hoffmann-La Roche, Ltd. (Switzerland) III-30
B.Market Analytics III-31
Table 27: Rest of Europe Recent Past Current & Future
Analysis for Antibacterial Drugs - Annual Sales Figures in
US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-31
3. ASIA-PACIFIC III-32
A.Market Analysis III-32
Focus on Select Regional Markets III-32
China III-32
Carbapenem Antibiotics Hold Great Potential III-32
India III-32
Injectable Antibiotics Demonstrate Robust Growth III-32
New Initiative to Develop Novel Antibiotic Molecules III-33
Products Introductions/Developments III-33
Strategic Corporate Developments III-34
Key Players III-36
B.Market Analytics III-38
Table 28: Asia-Pacific Recent Past, Current & Future
Analysis for Antibacterial Drugs by Drug Class -
Cephalosporins, Penicillins, Fluoroquinolones, Macrolides,
and Others Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-38
Table 29: Asia-Pacific 10-Year Perspective for Antibacterial
Drugs by Drug Class - Percentage Breakdown of Dollar Sales
for Cephalosporins, Penicillins, Fluoroquinolones,
Macrolides, and Others Markets for Years 2006, 2009 & 2015
(includes corresponding Graph/Chart) III-39
4. REST OF WORLD III-40
A.Market Analysis III-40
Strategic Corporate Developments III-40
B.Market Analytics III-41
Table 30: Rest of World Recent Past, Current & Future
Analysis for Antibacterial Drugs by Drug Class -
Cephalosporins, Penicillins, Fluoroquinolones, Macrolides,
and Others Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-41
Table 31: Rest of World 10-Year Perspective for
Antibacterial Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Cephalosporins, Penicillins,
Fluoroquinolones, Macrolides, and Other Markets for Years
2006, 2009 & 2015 (includes corresponding Graph/Chart) III-42
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled:124 (including Divisions/Subsidiaries - 127)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 26
Canada 1
Japan 5
Europe 27
France 3
Germany 4
The United Kingdom 3
Italy 3
Rest of Europe 14
Asia-Pacific (Excluding Japan) 67
------------------------------------------
To order this report:
Drug and Medication Industry: Global Antibacterial Drugs industry
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article